Share
The company will develop a Flu A/B, RSV and Covid-19 molecular multiplex test. Credit: Shameer Pk from Pixabay.

Cue Health has received a $28m federal contract for the development of Flu A/B, RSV and Covid-19 molecular multiplex tests for both point-of-care (POC) and over-the-counter applications.

The contract has been awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test is being developed to identify and distinguish the four viruses, delivering results in approximately 25 minutes.

Cue Health has also submitted an application to the US Food and Drug Administration (FDA), seeking emergency use authorisation (EUA) for its Cue Flu + COVID-19 Molecular Test.

Additionally, the company has applied to the FDA for the De Novo classification of the Cue RSV Molecular Test, seeking authorisation.

See Also:

In March this year, the corporation secured EUA from the FDA for the Cue Mpox (Monkeypox) Molecular Test, which can be used at POC at any CLIA-waived facility.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cue Health chairman and CEO Ayub Khattak said: “We expect this test will arm individuals and their providers with actionable information that can reduce community spread, increase the efficacy of treatment and help lead to better health outcomes.”

In 2020, Cue secured a contract from BARDA to boost the development, validation and FDA approval of its Covid-19 test.

It is claimed to be the first molecular test to obtain FDA EUA for over-the-counter and at-home use without a prescription.

Recently, the corporation secured De Novo authorisation from the FDA for the same Covid-19 test called the Cue Covid-19 Molecular Test. All molecular tests of the company run on the Cue Health Monitoring System.